Paradigm Shift in the Treatment of Patients With ACS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This protocol describes a pilot study intended to test the hypothesis that patients with acute coronary syndrome (ACS) caused by plaque erosion can be stabilized by effective antithrombotic treatment without stent implantation, thereby avoiding both early and late complications related to percutaneous coronary intervention (PCI).
Reduction of thrombus burden by OCT [ Time Frame: 30 days ]
The efficacy will be assessed by 50% reduction in thrombus burden by OCT at 1 month.
Secondary Outcome Measures :
Cardiovascular adverse events [ Time Frame: 30 days and 12 months ]
In patients treated conservatively, the safety objectives are to evaluate the occurrence of any adverse events during1 month follow up (re-infarction, re-hospitalization, revascularization by PCI or CABG, cardiac death, stoke, and major bleeding).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Men or non-pregnant women >18 years of age and < 75 years of age
Patients undergo cardiac catheterization for ACS. Patients with STEMI, NSTEMI, and UAP will be included. STEMI will be defined as continuous chest pain for >30 minutes, arrival at the hospital within 12 hours from chest pain onset, ST-segment elevation >0.1 mV in at least two contiguous leads, or new left bundle-branch block on the 12-lead electrocardiogram (ECG), and elevated cardiac markers (troponin T/I or creatine kinase-MB). NSTEMI will be defined as a progressive crescendo pattern of angina or angina at rest, in the absence of ST-segment elevation on the 12-lead ECG, with elevated cardiac markers. UAP will be defined as new onset angina, progressive crescendo pattern of angina, or angina at rest.
Culprit lesion located in a native coronary artery
TIMI flow grade 3 and diameter stenosis < 70% on angiogram
Definite erosion defined by OCT
Patients able to provide written informed consent
Left ventricular ejection fraction < 30%.
Life expectancy < 1 year.
Contraindication to the contrast media.
Creatinine level > 2.0 mg/dL or end-stage kidney disease.
Serious liver dysfunction.
Patients with hemodynamic or electrical instability (including shock).
Any contraindication against the use of ticagrelor.
Investigator considers the patient is not suitable.